Research & Development

Publications

Disclaimer

Etripamil is an investigational new drug which is not approved for commercial distribution in the United States. The publications in this section are for educational purposes to discuss clinical data relating to the investigational new drug. Etripamil has not been shown to be safe and effective for FDA approval purposes.

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID Study

In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient.

Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia

Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study

Etripamil Nasal Spray Reduces Heart Rate in Patients With Paroxysmal Supraventricular Tachycardia Prior to Conversion to Sinus Rhythm

Prevalence and Incidence of Patients with Paroxysmal Supraventricular Tachycardia in the United States

This study utilized claims data from both Medicare and private insurers to estimate the treated prevalence and incidence of PSVT in the U.S. over a 9-year period.

Analysis of Clinical Outcomes in the NODE-301 Trial

Etripamil Nasal Spray Relieves Symptoms and Reduces Emergency Room Interventions in Patients with Paroxysmal Supraventricular Tachycardia (PSVT).

Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.

This study explored the cost of health care spending in patients under the age of 65 three years before and three years after a PSVT diagnosis.

Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.

This study assesses gender differences in diagnosis, healthcare resource use, expenditures, and treatment.

Etripamil Nasal Spray For Acute Termination Of Spontaneous Episodes Of Paroxysmal Supraventricular Tachycardia.

Healthcare Resource Use and Expenditures in Patients Newly Diagnosed With Paroxysmal Supraventricular Tachycardia. American Journal of Cardiology. 2020.

This study explored the cost of health care spending in the year immediately before and after a PSVT diagnosis, segmenting patients above and under the age of 65.